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Abstract In May 2012, the Division of AIDS Research at
the National Institute of Mental Health (NIMH) organized
the “Global NeuroAIDS Roundtable” in conjunction with
the 11th International Symposium on Neurovirology and the
2012 Conference on HIV in the Nervous System. The meeting was held in New York, NY, USA and brought together
NIMH-funded investigators who are currently working on
projects related to the neurological complications of AIDS

(NeuroAIDS) in Africa, Asia, Eastern Europe, and Latin
America in order to provide an opportunity to share their
recent findings and discuss the challenges encountered within each country. The major goals of the roundtable were to
evaluate HIV-associated neurocognitive impairment and determine if it may be directly attributable to distinct HIV
subtypes or clades and to discuss the future priorities for
global NeuroAIDS research. At the “Global NeuroAIDS
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Roundtable”, presentations of preliminary research indicated
that HIV-associated neurocognitive impairment is prevalent
in all countries examined regardless of which HIV clade is
present in the region. The only clear-cut difference between
HIV-1 clades was in relation to subtypes A and D in Uganda.
However, a key point that emerged from the discussions was
that there is an urgent need to standardize neurocognitive
assessment methodologies across the globe before definitive
conclusions can be drawn regarding the relationship between
HIV clade diversity and neuropathogenesis. Future research
directions were also discussed at the roundtable with particular emphasis on the potential of viral and host factor molecular interactions to impact the pathophysiology of HIVassociated neurocognitive disorders (HAND) from a global
perspective.
Keywords Human immunodeficiency virus type 1 (HIV-1)
and type 2 (HIV-2) . Acquired immunodeficiency syndrome
(AIDS) . HIV clade . NeuroAIDS . HIV-associated
neurocognitive disorders (HAND) . Neuropathogenesis

Introduction
In May 2012, the Division of AIDS Research at the National
Institute of Mental Health (NIMH) organized the “Global
NeuroAIDS Roundtable” in conjunction with the 11th
International Symposium on Neurovirology and 2012
Conference on HIV in the Nervous System. This meeting
brought together NIMH-funded investigators who are currently working on the neurological complications of HIV/
AIDS (NeuroAIDS) projects in Africa, Asia, Eastern
Europe, and Latin America in order to provide an opportunity to share their recent findings and challenges encountered at their specific countries. The major goals of the
roundtable were to examine HIV-associated neurocognitive impairment and determine if it may be directly attributable to distinct HIV subtypes or clades from a global
perspective and to discuss the future priorities for global
NeuroAIDS research.
Africa region roundtable
Dr. Sacktor presented data evaluating the impact of HIV-1
clade or subtype on the risk of dementia among adults in
Uganda (Sacktor et al. 2009). In the USA, HIV-1 clade B is
the predominant HIV subtype, whereas in sub-Saharan
Africa HIV-1 clades A, C, and D are the predominant subtypes. Dr. Sacktor studied the relationship between HIV-1
subtype and the severity of HIV-associated cognitive impairment in 60 HIV-1 positive (HIV+) adults with advanced
immunosuppression (mean CD4 T lymphocyte count 0
127cells/mm3) initiating highly active antiretroviral therapy
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(HAART) in Uganda at risk for HIV-associated cognitive
impairment who received neurological, neuropsychological,
and functional assessments. Subtype assignments were generated by sequence analysis of the viral genome using a
portion of the gag and gp41 regions. Thirty-three HIV+
individuals were infected with HIV-1 subtype A, 2 with
subtype C, 9 with subtype D, and 16 with recombinants of
HIV-1 clades A and D (A/D recombinants). Eight of 9
(89 %) HIV+ individuals with subtype D had HIV-associated
dementia compared to 7 of 33 (24 %) HIV+ individuals with
subtype A (p00.004).
These results suggest that in untreated HIV+ adults with
advanced immunosuppression at risk for HIV-associated
cognitive impairment, HIV-associated dementia may be
more common among those patients with HIV-1 subtype D
than those with subtype A. Studies are currently underway
to evaluate HIV+ individuals with moderate immunosuppression. Further studies are needed to confirm this observation in other patient populations including HIV+ adults
verses children, and urban verses rural settings, and to
define the mechanism by which HIV-1 subtype D leads to
an increased risk of neuropathogenesis
Dr. Boivin then presented data comparing neuropsychological function by HIV-1 subtype (A versus D) in Ugandan
children. HIV subtype was determined by application of the
multiregion hybridization assay from plasma HIV RNA
(MHA). The MHA is particularly useful for identifying
recombinant forms as two different targets dispersed across
the HIV genome are simultaneously assessed. HIV-1 subtype was determined in 54 children (37 A, 16 D, 1 C; Boivin
et al. 2010). Subtype A infections had higher log viral loads
(median 5.0 versus 4.6, P 00.02). Children with HIV-1
subtype A performed more poorly than those with HIV-1
subtype D on all measures of neuropsychological function,
especially on the Kaufman Assessment Battery for Children,
second edition, even when adjusting for viral load levels.
The primary outcome variables were the global scores of
sequential processing (memory; P00.01), simultaneous processing (visual–spatial analysis; P00.005), learning (P0
0.02), and test of variables of attention visual attention
(P00.04). Based on these findings, it was concluded that
children infected with HIV-1 subtype A demonstrated
poorer neurocognitive performance compared to those children infected with subtype D. Subtype-specific neurocognitive deficits may reflect age-related differences in the
neuropathogenesis of HIV-1. This may have important
implications for when to initiate HAART and the selection
of drugs with greater penetration into the central nervous
system (CNS). Dr. Boivin’s group is presently replicating
these findings both in terms of neurodevelopmental assessment of Ugandan HIV-infected children less than 5 years of
age and neuropsychological assessment of HIV-infected
children between 5 and 12 years of age. They are also
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exploring the sensitivity of the relationship between HIV
subtype and neurocognitive effects when determining subtype from the HIV-1 Tat gene region. Although HIV-1
subtype D may be predisposed to CXCR4 tropism, HIV-1
subtype A strains can also acquire this phenotype in advanced disease. This may lead to a more virulent form of
HIV disease during critical periods of brain and behaviorial
development in children gestationally, peri- and postnatally.
What is more, many potential target cell types express both
CCR5 and CXCR4 co-receptors of HIV-1. In HIV-1 subtype
C infection, the viral regulatory protein Tat has been implicated as another variable affecting the development of
HAND in adults (Ranga et al. 2004). They are now trying
to confirm if the HIV-1 Tat gene serves a modifying role in
the development of encephalopathies in Ugandan children
infected by HIV-1 subtypes A versus D.
Dr. Kanmogne presented preliminary data showing increased neurocognitive impairment (NCI) among AIDS
patients in Cameroon compared to seronegative controls or
HIV-infected individuals without AIDS (Kanmogne et al.
2010). She also presented data on comparative analysis of
the circulating recombinant HIV-1 subtype CR02_AG, and
HIV-1 subtypes A, G, and B. The recombinant HIV-1
CRF02_AG is predominant in West and Central Africa,
but has also been spreading beyond Africa. Preliminary data
from Dr. Kanmogne and colleagues also showed that Tat
proteins from HIV-1 subtype B and CRF02_AG induced
differential effects on human brain endothelial cells in vitro
with subtype B significantly increasing the expression of
cytokines and matrix metalloproteinases compared to Tat
protein from HIV-1 CRF02_AG (Kanmogne et al., manuscript in preparation). Studies are underway to determine the
effects of HIV genotype on viral replication and NCI in
infected individuals in Cameroon.
Dr. Royal discussed his data from Nigeria where patients
are currently recruited into NeuroAIDS studies at two sites
in Abuja, the capital city. In previous studies, patients were
examined for cognitive impairment using the International
HIV Dementia Scale (IHDS) and it was found that, among
treatment-naïve infected subjects, a cutoff of 9 correlated
with an increased frequency of clinical impairment, as demonstrated by a Karnofsky status scale score of <50 (Royal et
al. 2012). The strains of virus that account for approximately
90 % of infections in Nigeria are HIV-1 subtypes G and
CRF_AG. In preliminary studies involving seven patients, it
was found that all of four patients infected with CRF_AG
were cognitively normal whereas two of three patients
infected with subtype G demonstrated evidence of NCI.
Studies are now underway that involve examining patients
using a detailed neuropsychological battery. To date, these
studies demonstrate the presence of impairment in infected
individuals compared to seronegatives in speed of information
processing, learning, executive functions, memory, and on the
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overall battery. Studies are ongoing to determine the
population-based frequency and incidence of NCI, the effect
of antiretroviral therapy and the links for monocyte-derived
virus with impairment among infected individuals.
Dr. Wood discussed data relating to his studies examining
HIV-1 clade C effects on neuropsychological function as
well as his neuropathology studies in Zambia. Over 200
postmortem brains have been collected from individuals
who died of AIDS in Zambia. Brain sections collected were
cortex (frontal, parietal, temporal, occipital), sub-cortex
(basal ganglia), hippocampus, and brain stem. So far, from
their preliminary analysis, they found a high frequency of
meningitis in addition to viral expression in brain.
Mycobacterium tuberculosis (MTB) and fungus were evident in most of the analyzed tissues. The findings support
previous reports indicating that HIV-1 subtype C does not
induce HIV encephalitis (HIVE) since the most common
finding was meningitis and only one case was found consistent with HIVE. Though these preliminary findings can
be biased since most cases were obtained from individuals
that died at the hospital, were HIV-1 positive, and the stage
of HIV disease of these selected cases had not been determined. The high prevalence of opportunistic infections
(OIs) found could indicate that these cases were in latestage disease; however, in a region where high MTB is
endemic and fungal infections are prevalent, this also cannot be definitely concluded. Therefore, it is likely that OIs,
together with HIV-1, play a role in the development of
neuropathology. They are now continuing to analyze additional brain specimens and to determine the correlation
between HIV-1 disease progression with OIs, meningitis,
and HIV-1 neuroinvasiveness. Dr. Wood also presented
preliminary findings from neuropsychological evaluations
and found 22 % impairment in HIV-1 clade C-infected
subjects based on IHDS (Holguin et al. 2011).
Dr. Paul presented studies from Cape Town, South
Africa where HIV-1 clade C is predominant and his findings revealed significant impairments on tests of cognitive
function among HIV-positive individuals. Further, work
from their group in South Africa suggests that structural
magnetic resonance imaging abnormalities are evident
among individuals infected with HIV-1 clade C, with
reduced volumes in the total white matter, thalamus, and
total gray matter. Preliminary data also suggest that volumes of the thalamus and putamen are smaller among
individuals infected with HIV-1 clade C than individuals
infected with HIV-1 clade B when compared with respective seronegative control groups (unpublished work).
Collectively, the neuropsychological and neuroimaging
studies provide evidence that HIV-1 clade C has significant neurotoxic consequences and additional work is
needed to determine the specific mechanisms associated
with these brain abnormalities.
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Dr. Clifford discussed his studies relating to HIV-2,
which is endemic in West Africa and results in chronic
retroviral infection that is not rapidly fatal in most cases.
Neurological involvement that is common in HIV-1 has not
been widely assessed in HIV-2, and potentially could be a
model of chronic retroviral infection of the CNS. Evaluation
of neurological manifestations in HIV-2 compared with
matched negative patients from two West African cohort
studies were carried out supported by an R21 grant to
Washington University in St. Louis, MO, USA. The cohorts
included the Medical Research Council Laboratories supported community cohort in Caio, Guinea–Bissau and the
sex worker cohort in Dakar, Senegal. Cross-sectional evaluations were performed by trained teams in each of the cohort
centers. The IHDS was a common tool for assessing CNS
performance. Data from the Caio cohort has been published
(Choi et al. 2011). In Dakar, HIV-2 positive and negative
populations were well matched, except for CD4 counts that
were lower in HIV positives. No evidence of performance
deficits was detected in HIV-2 positives compared to negative
subjects. Similarly, on exam, there was no evidence of excess
peripheral sensory neuropathy measured by distal vibratory
sense or pin prick sensations, nor in neuropathic signs or
symptoms. No myelopathy was found in this population
screened to exclude HTLV-1 affected patients. These findings
were qualitatively similar to what was found in the Guinea–
Bissau cohort. A combined analysis is planned. In summary,
Dr. Clifford’s studies found little evidence of clinically significant central or peripheral neurologic dysfunction in chronically HIV-2 infected patients. While these immunologically
intact HIV-2 patients do not have serious neurologic dysfunction, more subtle dysfunction not detected by the relatively
coarse tests cannot be ruled out. Additionally, they cannot rule
out development of these problems after longer exposure and
progression of immunodeficiency.
The project succeeded in training teams at two African
sites to perform quantitative evaluations and in translational
research methodology. The foundation created with this
project has already generated several large, collaborative
West African translational research projects. These include
the West African Network for Tuberculosis, AIDS and
Malaria funded by the European and Developing Clinical
Trial Partnership and the West African Platform for HIV
Intervention Research funded by the Global Health Research
Initiative of the International Development Research Centre of
Canada. Thus, significantly augmented research will be carried out in this region, in part spurred by the work and
investment in this project.
Asia region roundtable
Dr. Marcotte presented preliminary findings from collaboration between investigators at the University of California-San
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Diego, USA and the National AIDS Research Institute in
Pune, India. This study is enrolling approximately 250 HIV
seronegative controls and 250 HIV+ participants; assessing
them using a comprehensive neuropsychological (NP)
test battery and following them annually as they initiate
HAART. The investigators are developing both baseline
and longitudinal NP normative data. Analyses of the
baseline data indicate that when examining age, education, and gender-adjusted T scores, there is a stair-step
effect of disease status on cognition. Individuals with
HIV-1, but without an AIDS diagnosis, perform significantly worse than controls, and the group with AIDS
performs worse than both of the other groups. There is
a slight increase in the prevalence of overall NP impairment in the non-AIDS group (<10 % higher than
controls), with the greatest impairment (~40 %) seen in
the AIDS cohort. Overall, early indications are that the
neuropsychological impairment rates are not dramatically different from those seen in HIV-1 clade B. At 1 year,
preliminary analyses suggest modest cognitive benefits
of starting HAART in the non-AIDS and AIDS groups.
Ongoing analyses are also focused on investigating the
role of viral genetics and host factors (genetics, biomarkers) in the development of HAND.
Dr. Kumar gave a brief summary of his investigations
carried out on HIV-1 clade C-infected individuals in
Bangalore (South India) and Chandigarh (North India).
Since HIV-1 Tat protein structure in clade C infection has
serine replacing cysteine (impacting on monocyte transmigration into the brain), it had been believed that cognitive
deficits may not be occurring among HIV-1 Clade Cinfected individuals. However, it was shown that in India,
occurrence of neurocognitive deficits among HAART naïve,
HIV-1 clade C-infected individuals was similar to that
occurring in the West with HIV-1 clade B infection (Gupta
et al. 2007). It was also reported that inflammatory cytokines and virological markers were significantly increased
in cerebral spinal fluid (CSF) of infected individuals (Kamat
et al. 2009). A critical gap for research in India is the lack of
normative data from HIV negative comparison groups. Dr.
Kumar’s group has recently obtained normative neurocognitive data from a group of 200 non-infected individuals and
their findings are being published soon.
Dr. Pardo provided details of collaborative studies
underway at the National Institute of Mental Health and
NeuroSciences (NIMHANS) in Bangalore, India and the
National Brain Research Centre in Manesar, India.
Neuropathological studies of opportunistic infections in
NeuroAIDS at NIMHANS have disclosed a high frequency
of cryptococcal disease (32 %) and toxoplasma encephalitis
(25 %) among 170 autopsy cases from patient’s naïve to
HAART. All of these patients were infected with HIV-1 clade
C (Mahadevan et al. 2007). Immunopathological studies
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performed at Dr. Pardo’s lab also showed that infiltration by T
regulatory CD4 cells (Tregs), a critical cell population for
regulation of immune response, was particularly decreased
in brain tissues from Indian patients with OIs as compared
with brain tissues of patients from the USA with OIs infected
by HIV-1 clade B. These findings may suggest a potential
pathogenic role for the dysregulation of Tregs in patients with
OIs and that the Tregs may be influenced by the HIV-1 clade.
Dr. Heaton presented data from a study that evaluated the
rates, predictors, and consequences of neurocognitive impairment and neurocognitive decline over time, in two distinct groups of HIV-infected (HIV+) adults in China: former
plasma donors (FPDs) in rural Anhui province, who were
exposed to HIV due to use by some commercial blood
collection companies of nonsterile methods during the
1980s and early 1990s and heroin injection drug users
(IDUs) who were recruited from government-mandated
methadone treatment programs in the more urban and affluent Yunnan province. Large samples of demographically
comparable HIV uninfected (HIV−) controls were recruited
from the respective risk groups in both provinces. Compared
to their IDU counterparts, the HIV+ FPDs were older, much
less educated, and had much lower family incomes; they
also had HIV infection much longer, were more likely to
have AIDS and to be taking HAART, had lower nadir and
current CD4 cell counts, and were more likely to have
neurocognitive impairment at baseline (35 % vs. 22 %).
The lower rates of neurocognitive impairment in HIV+
IDUs vs. FPDs were seen only in those with early stage
disease (non-AIDS, 15.8 % for IDUs versus 28.9 % for
FPDs); those with more advanced disease (AIDS) had higher
rates of impairment regardless of their infection risk group
(38.6 % for IDUs and 40.0 % for FPDs). Neurocognitive
impairment in both groups was associated with low nadir
CD4 cell counts and more complaints of cognitive difficulties in everyday life; in Yunnan IDUs impairment was related
to duration of infection, AIDS status, unemployment, decreased independence in activities of daily living, and depressed mood; in HIV+ Anhui FPDs, impairment was related
to being on HAART and having low current CD4 levels.
Anhui FPDs were followed for up to 4 years and Yunnan
IDUs up to 3 years. Thirty-one HIV+ (no HIV−) participants
across both provinces died during the study; compared to
HIV+ who completed the longitudinal study, those who died
had higher HIV viral loads at baseline, as well as greater
neurocognitive impairment, more depressed mood, and
were less likely to be married. Over the follow-up period,
HIV− controls and HIV+ IDUs and FPDs had comparable
rates of neurocognitive improvement (all 10 %), but the
HIV+ were much more likely to show neurocognitive decline
(26 % for IDUs and 39 % for FPDs, vs. 12 % for controls).
These studies demonstrate that HIV infection, especially
with advanced disease, was associated with increased rates
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of neurocognitive impairment and neurocognitive decline
over time in these Chinese cohorts. Neurocognitive impairment increased the likelihood of everyday functioning difficulties and early mortality.
Dr. Sithinamsuwan discussed her studies relating to the
characterization of neurocognitive impairment among individuals infected with HIV-1 clade CRF01_AE in Thailand.
This clade accounts for about 90 % of HIV infection in
Thailand. This work was completed primarily within the
South East Asia Research Collaboration with Hawaii
(SEARCH) in Bangkok, Thailand among several trials:
SEARCH 001 and SEARCH 002 (ClinicalTrials.gov
Identifier NCT00864292 and NCT00713752, respectively),
and SEARCH 005.
The result from SEARCH 001 illustrated that depressive
symptoms were more frequent in HAD (n015) compared to
nondementia cases (n015; Valcour et al. 2007). They also
identified a pattern of neuropsychological testing impairment in HIV-1 clade CRF01_AE, with substantial impairments noted in verbal learning, memory and visuospatial
skills compared to a matched nondementia group. As
expected, all of these areas improved after initiation of
HAART; however, the HAD group tended to have less
complete recovery compared to the nondementia group.
The deficits noted in psychomotor speed, learning, and
memory were consistent with findings from HIV-infected
subjects infected with HIV-1 clade B. In contrast to other
clades, they did not identify a predominance of motor deficits in this cohort, which may suggest a potential difference
by HIV-1 clade; however, cultural factors, severity of disease, or clade-specific influences may all play a role.
The SEARCH 005 study investigated the frequency of
neurocognitive impairment and psychiatric co-morbidity
among 64 Thais who had been maintained on nonnucleoside reverse transcriptase inhibitor-based HAART
with undetectable plasma viral load for years within the
2NN cohort. Their goal was to demonstrate frequent impairment despite monitored and persistently suppressed plasma
HIV RNA. This study identified HAND in 37.5 % of
enrollees: 20.3 % with asymptomatic neurocognitive impairment (ANI), 15.6 % with mild neurocognitive disorder
(MND) and 1.6 % with HAD (Pumpradit et al. 2010). The
rate appeared to be somewhat lower than that described in
the USA (47 % prevalence of HAND) from the CHARTER
study; however, the CHARTER cohort included a substantial number of individuals with detectable plasma HIV RNA
known to impact cognition (Heaton et al. 2010). The authors
concluded that HAND remained frequent even in wellcontrolled Thai individuals, presumably infected with HIV1 clade CRF01_AE virus.
Dr. Letendre discussed a randomized phase 4 clinical trial
in China comparing a better-penetrating HAART regimen
(zidovudine–lamivudine–nevirapine) to a worse-penetrating
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comparison HAART regimen (tenofovir–lamivudine–efavirenz) on the prevention of HAND. The project is based
at two HIV clinics in Beijing, China and has a targeted
enrollment of 250 subjects, 233 of whom have been randomized as of May 2012 (ClinicalTrials.gov Identifier:
NCT01340950). The project will investigate the impact of
immune activation and viral hepatitis on the relationship
between treatment arms and incident neurocognitive decline
over 96 weeks of observation. The project also includes an
exploratory pharmacogenomics aim and has received supplemental funding for lumbar punctures and magnetic resonance spectroscopy. The final primary endpoint visit is
expected to occur in the third quarter of 2013.
Latin America, Eastern Europe, and global multisite studies
roundtable
Dr. Brew described studies related to assessing HIV-1 related
neurologic disease in the Asia Pacific region. He outlined the
activities of the Asia Pacific NeuroAIDS Consortium
(APNAC) which has performed cross-sectional outpatient
and inpatient studies in Thailand, Papua New Guinea, Fiji,
Malaysia, Cambodia, Indonesia, China, and Hong Kong
(Wright et al. 2008). While the majority of the sites are
known to have mixed HIV clade populations, this is not the
case in the Papua New Guinea site where HIV-1 clade C is
overwhelmingly dominant. Across the APNAC sites, neurocognitive impairment was found to be common among the
658 participants (161 HIV-negative matched controls) with
rates of moderate to severe disease across the region of 12 %,
not dissimilar to rates in developed countries. When the
whole spectrum of HAND was included the figures ranged
from 25 to over 50 %, again very similar to the developed
countries. The rates varied according to region rather than any
obvious influence of HIV-1 clade; the variability likely related to some selection bias in the populations studied.
Importantly, however, when Papua New Guinea is considered, the rates were 53 % for ANI/MND and 18 % for HAD.
Symptomatic sensory neuropathy was found in approximately 20 %, similar to data from developed countries. These data
argue strongly against any significant impact of HIV clade on
HAND and neuropathy and particularly argue against any
mitigating effect of HIV-1 clade C on HAND.
Dr. Robertson discussed findings from the AIDS
Clinical Trials Group (ACTG) A5199. The International
Neurological study (Robertson et al. 2011) which compared the neurological and NP effects of three HAART
regimens in 860 HIV-1-infected participants in the
resource-limited settings (RLS). The goal of the study
was to assess prevalence of HIV-related neuropsychological and neurological dysfunction in RLS, to assess whether
there was any neurocognitive advantage between initial
recommended treatment regimens for RLS, and to assess
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incidence of HIV-related neuropsychological and neurological dysfunction in RLS on antiretroviral treatment.
Participants from Brazil, India, Malawi, Peru, South
Africa, Thailand, and Zimbabwe were randomized to three
HAART treatment arms: A (lamivudine-zidovudine plus
efavirenz, n 0289), B (atazanavir, emtricitabine, and
didanosine–EC n0293), and C (emtricitabine–tenofovir–
disoproxil fumarate plus efavirenz, n0278) as part of the
ACTG PEARLS study (A5175). Standardized neurological
and NP screening examinations (grooved pegboard, timed
gait, semantic verbal fluency, and finger tapping) were
administered every 24 weeks from February 2006 to May
2010. Associations with neurological and neuropsychological function were estimated from linear and logistic regression models using generalized estimating equations. There
was an extensive period of follow-upon HAART for over
3 years with the median weeks on study at 168 (Q1096,
Q30192) for the 860 participants.
The study detected no significant differences in neuropsychological and neurological outcomes between randomized HAART regimens. Significant improvement occurred
in neurocognitive and neurological functioning over time
after initiation of HAART. The etiology of these improvements is likely multifactorial, reflecting reduced HIV-1 infection of the CNS, better general health and practice
effects. This study suggests that treatment with either of
the WHO-recommended first-line antiretroviral regimens
in resource-limited settings will improve neuropsychological functioning and reduce neurological dysfunction
(Robertson 2011).
Significant country variation was noted in neuropsychological and neurological variables, which are likely multifactorial including site differences in culture and education.
Differences in underlying HIV subtype are present and
cannot be excluded as the cause of the country variation in
neuropsychological and neurological outcomes as of yet.
Specific subtyping of the study participants is underway
and will yield more conclusive results.
Dr. Achim presented data derived from studies (in collaboration with Dr. Victor Babes Hospital in Bucharest) of a
long-term cohort of young adults in Romania who were
infected with HIV-1 clade F as children. In a preliminary
study using a sample of 49 HIV+ and 20 HIV− participants
and comparing raw score neuropsychological performance,
they saw moderate-to-large effect sizes across all neuropsychological measures, with significant differences in the neurocognitive domains of fluency, speed of processing,
attention/working memory, executive functioning, and motor skills. Since Romanian-specific normative data do not
exist, it is difficult to establish “impairment” within individual participants. However, in order to at least estimate impairment rates in their pilot feasibility study, they applied
normative data (adjusting for age, education, and gender)
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that were gathered in the USA from a Spanish-speaking
cohort (using Spanish language measures), since, unlike
typical US norms, these provide adequate adjustments for
individuals with lower levels of education. Using this approach, T scores for the Romanian controls were generally
around 50, which is what one would expect if the norms
were appropriate for the study group. Using data corrected
with these norms, they calculated a global deficit score
(GDS), which provides an estimate of overall cognitive
functioning. Worse cognitive performance results in a
higher GDS. A GDS score of >0.71 was the cutoff point
where 15 % of HIV− controls were classified as impaired
(mirroring the procedure used in their US studies). Using
this score, they found that 47 % of the HIV+ cohort was
classified as having neurocognitive impairment.
All HIV+ participants had a current CD4 cell count
greater than 200. In order to examine whether there was a
relationship between CD4 cell levels and cognition, they
split the group at a CD4 cell count of 350 (the current
guideline for starting antiretroviral treatment). Using the
GDS as an estimate of overall cognitive functioning, within
the HIV+ group there was no difference between those with
a current CD4 <350 (GDS00.91; n015) and those with a
CD4 cell count >350 (GDS00.94; n029). However, there
was a trend for those with a nadir CD4 <200 (GDS01.04;
n034) to have a higher GDS than those who never dropped
below 200 (GDS00.65; n013, p00.11).
The results of this feasibility study suggest that the translated neuropsychological measures are valid and sensitive to
the effects of HIV-associated brain injury in this Romanian
cohort. The HIV+ participants had worse neurocognitive
functioning than the HIV− group, despite being matched
in terms of socioeconomic background. Thus, even though
the participants in this study were long-term survivors of
infection that occurred during early childhood and had up to
a decade of effective antiviral treatments that currently render them immunocompetent with good viral suppression, a
significant proportion still have evidence of HAND.
Importantly, their findings are not only of interest in the
Romanian context, as worldwide it is estimated that 2.3
million children under the age of 15 are living with HIV.
Dr. Ellis discussed studies of neurocognitive impairment
using a comprehensive neuropsychological assessment and
the IHDS in HIV-1 clade B- and C-infected individuals from
the same geographic region in southern Brazil. They studied
52 HIV+ and 40 HIV−/HCV− subjects from 2007 to 2011 in
Curitiba, Brazil. All the HIV+ participants were recruited
through the Hospital de Clinicas UFPR and Parana State
Health Secretary; HIV− participants were recruited from
blood banks. Blood and CSF were collected from all HIV+
participants. All participants were evaluated with an adaptation of the HIV Neurobehavioral Research Center
(HNRC) neuropsychological battery for testing in
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Brazilian Portuguese, as well as the IHDS. HIV+ (n052)
and HIV− participants (n040) were comparable on demographic characteristics. Among HIV+ participants, median
CD4 nadir was 90 [IQR 36–266] and median log10 plasma
HIV RNA was 1.68 [IQR 1.68–3.52]. Clade B (n027)- and
C (n025)-infected individuals were similar with respect to
demographic and HIV disease variables with the exception
of plasma viral load, which was lower in clade B subjects
than in clade C (median [IQR], 1.7 [1.7, 1.9] vs. 2.9 [1.7,
3.8]; p 00.008); clade B-infected individuals were also
more likely to be on HAART (81 % versus 56 %). HIV+
individuals had a significantly higher rate of neurocognitive impairment than HIV- by the GDS (60 % vs 17 %).
Impairment rates among HIV-1 clade B- and C-infected
individuals did not differ significantly (65 % vs. 55 %).
There was no significant difference in IHDS scores or in
IHDS impairment rates between HIV-1 clade B- and Cinfected individuals (11.0 [9.0–12.0] vs. 12 [9.8–12]; p0
0.21; 44 % vs. 28 %, p00.22; Cohen’s d00.17), even after
adjusting for plasma viral load (p00.83). In summary, the
HNRC NP battery was successfully adapted for use in
Brazilian Portuguese speakers. When ascertained using
comparable methods, clade B and C HIV infections in the
same geographic region did not differ in their rates of
neurocognitive impairment. Similarly, the prevalence of
pleocytosis, an indirect marker of intrathecal cellular chemotaxis, did not differ between clade B and C infections.

Discussion
Drs. Grant, Clifford, and Valcour provided a summary of the
key findings presented at the “Global NeuroAIDS
Roundtable” and led a discussion focused on future directions for the field. Dr. Grant stated that data from at least 11
countries were presented and HAND was prevalent in all
these regions. However, HAND was not associated with
HIV-2 infection based on studies conducted by Dr.
Clifford’s group in West Africa. With regard to the impact
of HIV-1 clade on HAND, the results depended on the
subtypes that were compared and were somewhat mixed.
The indirect data presented comparing HIV-1 clade B and
clade C indicated a similar clinical prevalence of HAND.
For example, when impairment rates in India and Thailand
were compared to rates found in prior studies in the USA,
the rates were found to be similar. In a more direct and
compelling comparison of HIV-1 clade B and C in the same
populations in Brazil, Dr. Ellis found the same rates of
neurocognitive impairment across these two clades. In a
comparison of different clades, Dr. Sacktor in his studies
in Uganda found that HIV-1 associated dementia was more
common among those patients with subtype D than those
with subtype A. A potential mechanism driving this
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difference may be related to co-receptor usage. For example,
HIV-1 clades A and C use the CCR5 co-receptor for viral
entry which is nonsyncytium inducing, macrophage tropic,
and associated with slower viral growth. Whereas HIV-1
subtype D is dual tropic and CXCR4 T cell tropic strains
have more rapid viral growth and replication causing more
rapid HIV disease progression. The differences in neurocognitive impairment seen between HIV-1 subtypes A and
D may in part be linked to HIV disease progression.
In direct contrast to this adult data from Uganda, Dr.
Boivin presented studies which indicated that in children
infected by HIV-1 poorer neurocognitive performance was
demonstrated with subtype A when compared to subtype D.
HIV-1 subtype A is associated with CCR5 tropism and this
may confer the advantage of infecting macrophages associated with an encephalitis disease outcome. In sensitive periods of the development of children, CCR5–tropic strains
may be more “encephalopathogenic”. If this is true, it does
raise some very important questions about the effects of
HIV-1 clades and other factors that may operate differently
in the context of neurodevelopment verses a mature nervous
system.
A number of issues need to be considered while interpreting the data presented relating to HIV clade diversity
and neuropathogenesis at the “Global NeuroAIDS
Roundtable”. Many speakers spoke of the importance of
using standardized methods for neurocognitive assessments
as a current challenge to addressing the question of the
effects of HIV-1 clade on HIV-associated neurocognitive
impairment. An interesting example was in Dr. Royal’s
presentation where in his pilot work he had a rate of 22 %
cognitive impairment using the IHDS and then he had a rate
of about half of people impaired using a more comprehensive battery that had been standardized. This finding demonstrates an important limitation of using shorter-screening
batteries to identify individuals with neurocognitive impairment. In addition, neurocognitive assessment batteries need
to take into account local cultural, language, and socioeconomic factors when determining rates of neurocognitive
impairment.
It is also critical to delineate the type of neurocognitive
impairments that are being defined in relation to HIV-1
clades and those delineated by HAND. HAND encompasses
asymptomatic neurocognitive impairment, minor cognitive
disorders and HIV-associated dementia. The earlier studies
demonstrating HIV-1 clade differences were studying the
more severe HIV-associated dementia cases from patients in
India infected with HIV-1 clade C. Thus, HIV-1 clade differences, if present, may only be apparent if similar types of
impairment stratifications are compared.
The treatment status of the patients and the types of
HAART regimens being administered also needs to be taken
into account when assessing the impact that HIV-1 clades
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have in inducing neurocognitive impairment. HAART is
known to make a difference in neurocognitive outcomes
and different drug combinations have distinct characteristics
with respect to their CNS penetration.
Another issue to consider is that HIV-1 subtype C viruses
may demonstrate heterogeneity based on their geographic
origins. New emerging data suggests it is important to group
clade C into CC vs. CS variants since geographic differences in their distribution have been found (Prasad et al.,
personal communication). These viral variants may have
differential impacts on neurocognitive outcomes.
There was also a discussion about future research areas to
better define the potential mechanisms of HIV-1 clade specific effects on HAND. Some of the areas for future research
include (1) identification of HIV clade specific neurovirulent and/or neurotropic signature sequences; (2) delineation
of potential viral clade specific differences in interaction
with co-morbid conditions; (3) study of HIV clade specific
developmental effects in relation to neuropathogenesis; (4)
assessment of the differential impact on neurocognitive outcomes resulting from unique interactions of antiretroviral
medications with different viral clades; (5) study of HIV
clade specific differences in LTR transactivation; (6) assessment of the impact of variations in HIV clade on establishment of viral set points; and (7) study of a potential
pathogenic role for HIV-1 clade specific dysregulation of
Tregs in patients with OIs.

Conclusions
The preliminary findings presented at the “Global
NeuroAIDS Roundtable” indicated that HIV-associated neurocognitive impairment is prevalent in all countries examined despite the HIV-1 subtype distribution in the region.
The only clear-cut difference between HIV-1 subtypes on
neurocognitive impairment was seen in relation to subtypes
A and D in Uganda. However, a key point emerging from
the discussions was that there is an urgent need to standardize neurocognitive assessment methodologies across the
globe before definitive conclusions can be drawn regarding
the relationship between HIV-1 clade diversity and neuropathogenesis. A number of research directions were also
discussed particularly with reference to studies of potential
mechanisms of interaction of viral and host factors in the
pathophysiology of HAND from a global perspective.
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